Citi reiterated its Buy rating on Bristol Myers Squibb BMY. At the same time, the rating agency raised its price target on the company's stock from $30 to $39. On Monday, BMY lost 0.38% of its value to finish the day at $28.55. Its shares continued to slide in today's pre-market trading, falling 0.07% to stand around $28.53.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
